Despite the accumulated data supporting the function of TSLP as a therapeutic target for pruritus, tezepelumab could not achieve statistically significant improvements in pruritus for atopic dermatitis in Phase 2A clinical trial (NCT02525094); and the company has abandoned its development for this indication.135, 136, 137. The gene discussed is TSLP; the disease is atopic eczema.